Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours

Journal of Clinical Pathology

Volumn 52, Issue 7, 1999, Pages 481-489

  Graadt Van Roggen, J F ^a   Bovee J V M G ^a   Morreau, J ^a   Hogendoorn, P C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone tumours; Molecular biology; Soft tissue tumours

Indexed keywords

ARTICLE; BONE TUMOR; CYTOGENETICS; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; MESENCHYMOMA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; SOFT TISSUE TUMOR;

EID: 0033023052     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.7.481     Document Type: Article

References (85)

1. 1 Sadler TW. Langman's medical embryology, 6th ed. Baltimore: Williams and Wilkins, 1990.
2. 2 Enzinger FM, Weiss SW. Soft tissue tumours, 3rd ed. New York: CV Mosby, 1995.
3. 3 Rydholm A, Berg NO, Gullberg B, et al. Epidemiology of soft tissue sarcoma in the locomotor system: a retrospective population-based study of the inter-relationships between clinical and morphological variables. Acta Pathol Microbiol Immunol Scand 1984;92A:363-74.
4. 4 Silverberg E, Boring CC, Squires TS. Cancer statistics. CA Cancer J Clin 1990;40:9-26.
5. 5 Presant CA, Russell WO, Alexander RW, et al. Soft tissue and bone sarcoma histopathology peer review; the frequency of disagreement at diagnosis and the need for second pathology opinions: the Southeastern Cancer Study Group experience. J Clin Oncol 1986;4:1658-61.
6. 6 Fletcher JA. Cytogenetics and molecular biology of soft tissue tumors. In: Weiss SW, Brooks JSJ, eds. Soft tissue tumours, chapter 2. New York: Williams and Wilkins, 1996.
7. 7 Fletcher JA, Kozakewich HP, Hoffer FA, et al. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft tissue tumors. N Engl J Med 1991;324:436-42.
8. 8 Sreekantaiah C, Ladanyi M, Rodriguez E, et al. Chromosomal aberrations in soft tissue tumors. Am J Pathol 1994; 144:1121-34.
9. 9 Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 1995;4:162-73.
10. 10 Melo JV. The diversity of bcr-abl fusion proteins and their relationship to leukaemia phenotype. Blood 1996;88:2375-84.
11. 11 Sandberg AA. The chromosomes in human cancer and leukaemia, 2nd ed. New York: Elsevier, 1990.
12. 12 Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-60.
13. 13 Zoubeck A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996;14:1245-51.
14. 14 Rabbitts TH. The clinical significance of fusion oncogenes in cancer. N Engl J Med 1998;338:192-4.
15. 15 Alberts B, Bray D, Lewis J, et al. Molecular biology of the cell, 2nd ed. New York: Garland Publishing, 1993.
16. 16 Pritchard DJ, Dahlin DC, Dauphine RT, et al. Ewing's sarcoma: a clinicopathological and statistical analysis of patients surviving 5 years or longer. J Bone Joint Surg Am 1975;57A:10-16.
17. 17 Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 1975;36:240-51.
18. 18 Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumour of the thoracopulmonary region in childhood. Cancer 1979;43:2438-51.
19. 19 Pagani A, Fischer-Colbrie R, Eder U, et al. Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence. Int J Cancer 1995;63:738-43.
20. 20 Fellinger EJ, Garin-Chesa P, Triche T, et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/p32 MIC2. Am J Pathol 1991;139:317-25.
21. 21 Stevenson AJ, Chatten J, Bertoni F, et al. CD99 (p30/ 32mic2) neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker: review of more than 600 tumours and the literature experience. Appl Immunohistochem 1994;2:231-40.
22. 22 Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-9.
23. 23 Delattre O, Zucman J, Plougastel B, et al Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
24. 24 Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genet 1994;6:146-51.
25. 25 Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to another ETS gene, ETV1. Oncogene 1995;10:1229-34.
26. 26 Meier VS, Kuhne T, Jundt G, et al. Molecular diagnosis of Ewing tumours: improved detection of EWS-FLI-1 and EWS-ERG chimaeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 1998;7:29-35.
27. 27 Giovannini M, Biegel JA, Serra M, et al. EWS-ERG and EWS-FLII fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest 1994;94:489-96.
28. 28 de Alava E, Kawai A, Healey JH, et al. EWS FLII fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-55.
29. 29 Ewing's sarcoma oncogene structure: a novel prognostic marker? [Editorial] J Clin Oncol 1998;16:1241-3.
30. 30 Downing JR, Head DR, Parham DM, et al. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcriptase polymerase chain reaction. Am J Pathol 1993;143:1294-300.
31. 31 Sorenson PHB, Shimada H, Liu XF, et al. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLII fusion gene. Cancer Res 1995; 55:1385-92.
32. 32 Noguera R, Navarro S, Triche TJ. Translocation (11;22) in small cell osteosarcoma. Cancer Genet Cytogenet 1990;45: 121-4.
33. 33 Sainati L, Scapinello A, Montaldi A, et al. A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q12). Cancer Genet Cytogenet 1993;71:144-7.
34. 34 Gerald WL, Miller HK, Battifora H, et al. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy involving young individuals. Am J Surg Pathol 1991;15: 499-513.
35. 35 Gerald WL, Rosai J, Ladanyi M. Characterisation of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci USA 1995;92:1028-32.
36. 36 de Alava E, Ladanyi M, Rosai J, et al. Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. Am J Pathol 1995;147:1584-91.
37. 37 Dias P, Parham DM, Shapiro DN, et al. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol 1990;137:1283-91.
38. 38 Barr FG, Biegel TA, Sellinger B, et al. Molecular and cytogenetic analysis of chromosomal arms 2q and 13q in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 1991;3:153-61.
39. 39 Barr FG, Galli N, Hollick J, et al. Rearrangement of the PAX3 paired box in the pediatric solid tumor alveolar rhabdomyosarcoma. Nature Genet 1993;3:113-17.
40. 40 Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-72.
41. 41 Dias P, Kumar P, Marsden HB, et al. N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer 1990;45:593-6.
42. 42 Kelly KM, Womer RB, Sorensen PHB, et al. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997;15:1831-6.
43. 43 Shimada H, Newton WA, Soule EH, et al. Pathology of fatal rhabdomyosarcoma: report of intergroup rhabdomyosarcoma study (IRS-I and IKS-III). Cancer 1987;59:459-65.
44. 44 Scrable H, Witte D, Shimada H, et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1989;1:23-35.
45. 45 Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science 1984;224:1121-4.
46. 46 De Lorimer AA, Bragg KU, Linden G. Neuroblastoma in childhood. Am J Dis Child 1969;118:441-50.
47. 47 Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
48. 48 Schleiermacher G, Peter M, Michon J, et al. A multiplex PCR assay for routine evaluation of deletion of the short arm of chromosome 1 in neuroblastoma. Eur J Cancer 1995;31A:535-8.
49. 49 Abe S, Imamura T, Park P, et al. Small round-cell type of malignant peripheral nerve sheath tumour. Mod Pathol 1998;11:747-53.
50. 50 Schmidt D, Thum P, Harms D, et al. Synovial sarcoma in adults and children: a report from the Kiel paediatric tumour registry. Cancer 1991;67:1667-72.
51. 51 Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci USA 1987;84:1981-5.
52. 52 Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genet 1994;7:502-8.
53. 53 Mandahl N, Helm S, Arheden K, et al. Multiple karyotypic rearrangernents including t(X;18)(p11;q11) in a fibrusarcoma. Cancer Genet Cytogenet 1988;30:323-7.
54. 54 de Leeuw B, Suijkerbuijk RF, Olde Weghuis D, et al. Distinct Xp11.2 breakpoint regions in synovial sarcoma revealed by metaphase and interphase FISH: relationship to histologic subtypes. Cancer Genet Cytogenet 1994;73:89-94.
55. 55 Renwick PJ, Reeves BR, Dal Cin P, et al. Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp11.2, with implications for the histologic sub-classification of synovial sarcoma. Cytogenet Cell Genet 1995;70:58-63.
56. 56 Argani P, Zakowski MF, Klimstra DS, et al. Detection of the SYT-SSX chimeric RNA of synovial sarcoma in paraffin-embedded tissue and its application in problematic cases. Mod Pathol 1998;11:65-71.
57. 57 Sorensen SA, Mulvihill JJ, Nielson A. Longterm follow-up of von Recklinghausen neurofibromatosis. N Engl J Med 1986;314:1010-15.
58. 58 Mertens F, Rydholm A, Bauer HF, et al. Cytogenetic findings in malignant peripheral nerve sheath tumours. Int J Cancer 1995;61:793-8.
59. 59 Jhanwar SC, Chen Q, Li FP, et al. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosomal abnormalities in malignant peripheral nerve sheath tumours (MPNST). Cancer Genet Cytogenet 1994;78:138-44.
60. 60 Skuse GR, Kosciolek BA, Rowley PT. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis:loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer 1989;1:36-41.
61. 61 Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NFI tumors. Genes Chromosomes Cancer 1994;10:250-5.
62. 62 Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction: Am J Surg Pathol 1992;16: 213-28.
63. 63 Taubert H, Berger D, Hinze R, et al. How is the mutational status for tumor suppressors p53 and p161NK4A in MFH of the bone? Cancer Lett 1998;123:147-51.
64. 64 Rydholm A, Mandahl N, Heim S, et al. Malignant fibrous histiocytomas with a 19p+ marker chromosome have increased relapse rate. Genes Chromosomes Cancer 1990;2: 296-9.
65. 65 Schoenmakers EFPM, Wanschura S, Mols R, et al. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nature Genet 1995;10:436-43.
66. 66 Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nature Genet 1998;18:184-7.
67. 67 Sankary S, Dickman PS, Wiener E, et al. Consistent numerical chromosome aberrations in congenital fibrosarcoma. Cancer Genet Cytogenet 1993;65:152-6.
68. 68 Pedeutour P, Simon MP, Minoletti P, et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma: a new tumour-associated chromosomal rearrangement. Cytogenet Cell Genet 1996:72:171-4.
69. 69 Enzinger FM. Clear cell sarcoma of tendons and aponcuroses: an analysis of 21 cases. Cancer 1965;18:1163-74.
70. 70 Graadt van Roggen JF, Mooi WJ, Hogendoorn PCW. Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. J Pathol 1998;186:3-7.
71. 71 Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nature Genet 1993;4:341-5.
72. 72 Sreekantaiah C, Karakousis CP, Leong SP, et al. Cytogenetic findings in liposarcoma correlate with histologic subtypes. Cancer 1992;69:2484-95.
73. 73 Turc-Carel C, Limon J, Dal CP, et al. Cytogenetic studies of adipose tumours. Recurrent reciprocal translocation t(12; 16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet 1986;23:291-9.
74. 74 Panagopoulns I, Mandahl N, Ron D, et al. Characterisation of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation. Cancer Res 1994;54:6500-3.
75. 75 Ashar HR, Fejzo MS, Tkachenko A, et al. Disruption of the architectural factor HMG-C1: DNA-binding A-T hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995;82:57-65.
76. 76 Sciot R, Akerman M, Dal Cin P, et al. Cytogenetic analysis of subcutaneous angiolipoma: further evidence supporting its difference from ordinary pure lipomas. Am J Surg Pathol 1997;21:441-4.
77. 77 Bridge JA, Bhatia PS, Anderson JR, et al. Biological and clinical significance of cytogenetic abnormalities in benign and malignant cartilaginous lesions. Cancer Genet Cytogenet 1993;69:79-90.
78. 78 Labelle Y, Zucman J, Stenman G, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995;4:2219-26.
79. 79 Brody RI, Ueda T, Hamelin A, et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. Am J Pathol 1997; 150:1049-58.
80. 80 Hecht JT, Hogue D, Strong LC, et al. Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome 11 and loss of hetorozygosity for EXT linked markers on chromosome 11 and 8. Am J Hum Genet 1995;56:1125-31.
81. 81 Raskind WH, Conrad EU, Chansky H, et al. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses foci on chromosome 8 and 11. Am J Hum Genet 1995;56:1132-9.
82. 82 Nawa G, Veda T, Mori S, et al. Prognostic significance of Ki-67 (MIB 1) proliferation index and p53 overexpression in chondrosarcomas. Int J Cancer 1996;69:86-91.
83. 83 Terek RM, Healey JH, Garin-Chesa P, et al. p53 Mutations in chondrosarcoma. Diagn Mol Pathol 1998;7:51-6.
84. 84 Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science 1998;279:577-80.
85. 85 Komuro H, Hayashi Y, Kawamura M, et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastoma. Cancer Res 1993;53:5284-8.